Introduction
============

The majority of physiological responses to hormones and neurotransmitters are mediated by G protein-coupled receptors (GPCRs). These integral membrane proteins relay signals elicited by an array of structurally diverse agonists including photons, ions, small organic compounds, peptides, proteins and lipids ([@b29]). GPCRs have been classically described as monomeric transmembrane receptors that form a ternary complex: a ligand, the GPCR, and its associated G protein ([@b7]; [@b14]). This classical view is compatible with observations that monomeric rhodopsin and β~2~-adrenoceptor (β~2~AR) are capable of activating G proteins ([@b5]; [@b12]; [@b59]). Nevertheless, it is now well accepted that Family C GPCRs are constitutive dimers ([@b31]; [@b40]; [@b16]), and many Family A GPCRs have been observed to oligomerize in cells. This was initially shown for the β~2~AR in 1996 ([@b28]), and was later followed by publications demonstrating both homo- and hetero-oligomerization of a broad spectrum of Family A GPCRs using a variety of techniques ([@b32]; [@b4]; [@b20]; [@b50]; [@b8]; [@b43]; [@b35]; [@b53]; [@b21]; [@b25]; [@b57]). Despite this evidence, the effect of ligands on formation, organization and stability of receptor oligomers, as well as the role of other cellular proteins, is not well understood and may be receptor subtype specific ([@b4]; [@b8]; [@b35]; [@b63]; [@b51]; [@b36]).

High-resolution crystal structures are now available for the inactive state of the β~2~AR ([@b9]; [@b49]; [@b52]); yet, we still know very little about the structure, stoichiometry and dynamics of oligomers in lipid bilayers. To date, much of what is known about oligomerization of β~2~ARs and other Family A GPCRs comes from elegant studies using intermolecular fluorescence/bioluminescence resonance energy transfer (FRET or BRET) in live cells ([@b4]; [@b53]; [@b45]). In an effort to complement these cell-based studies and better understand the process of GPCR oligomerization and the organization of protomers within oligomers, we investigated oligomerization of purified β~2~AR in a model membrane system. By site specifically labelling purified monomeric β~2~AR and reconstituting it into lipid vesicles, we are able to show that this receptor effectively forms specific multimeric assemblies in lipid bilayers as monitored by FRET and cross-linking studies. FRET saturation studies are most consistent with the formation of tetramers, and differences in FRET between different labelling pairs allow us to propose a model of the orientation of the protomers within the tetramer. An agonist and neutral antagonist have little effect on β~2~AR oligomerization, but the inverse agonist ICI 118,551 promotes rearrangement of the protomers and/or the formation of higher-order oligomers.

Results
=======

Site-specific labelling of purified monomeric *β*~2~AR and reconstitution into lipid vesicles
---------------------------------------------------------------------------------------------

The goal of our studies was to monitor self-association of β~2~AR following reconstitution in lipid vesicles and to obtain information about the relative orientation of protomers in oligomers. FRET using small-molecular-weight fluorescent probes is an ideal tool for these studies because it provides relative distance information yet requires relatively small amounts of protein ([@b39]). To achieve site-specific labelling of the β~2~AR, we generated modified receptors having single-reactive cysteines that can be chemically modified with sulphydryl-reactive fluorophores. Mutants were made on a minimal cysteine background in which the five chemically reactive cysteines, out of 13, were mutated (see section Materials and methods). These mutations have no effect on ligand binding or G protein coupling. The remaining three cysteines that are not palmitoylated or are part of disulphide bonds are not reactive due to their location in the hydrophobic core ([Figure 1A](#f1){ref-type="fig"}). We initially constructed 18 single-cysteine mutants in the cytoplasmic domains of the receptor. Three were chosen based on their functional properties, chemical reactivity and their distribution ([Figure 1B](#f1){ref-type="fig"}): Δ5-T66C (intracellular loop-1, ICL1), Δ5-A265C (transmembrane domain-6, TM6) and Δ5-R333C (helix-8, H8) ([@b9]; [@b49]; [@b52]). This spatial distribution of the labelling sites was designed to provide information about the orientation of protomers relative to each other.

Modified receptors were expressed in Sf9 cells using recombinant baculovirus and purified using sequential antibody and alprenolol affinity chromatography. We have shown previously that this purification protocol produces monomeric, detergent-solubilized β~2~AR ([@b59]). Purified, detergent-solubilized β~2~AR was labelled with Cy3 or Cy5 maleimide. These fluorophores were chosen for FRET studies because they possess an R~0~ value (Förster critical distance where 50% of energy transfer occurs) in the range of 37 to 56 Å depending on the experimental system ([@b39]; [@b41]). This is ideal for studying receptor--receptor interactions since a monomer has approximate dimensions of 30 Å × 40 Å × 70 Å. β~2~ARs were labelled with stoichiometric amounts of either Cy3 or Cy5, and the efficiency of labelling was determined by absorption spectroscopy ([Supplementary Table I](#S1){ref-type="supplementary-material"}). Labelled β~2~AR was reconstituted into a mixture of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and cholesterol hemisuccinate (CHS) lipids. Three samples were generated for each experiment: (1) reconstituted Cy3-labelled β~2~AR; (2) reconstituted Cy5-labelled β~2~AR and (3) Cy3-labelled β~2~AR mixed with Cy5-labelled β~2~AR and then reconstituted. The final lipid-to-receptor molar ratio (mol-to-mol) was 1000:1 unless otherwise indicated. The same samples were prepared for controls, but were maintained in 0.1% DM and not reconstituted into vesicles.

Orientation of *β*~2~AR in lipid vesicles
-----------------------------------------

Knowing the orientation of β~2~AR in our lipid vesicles is essential for interpreting FRET measurements. Random orientation would generate potential non-physiological (antiparallel) oligomers. While random orientation might be expected, previous studies have shown that rhodopsin orients predominantly in one direction following reconstitution ([@b46]). We used several complementary strategies to determine the orientation of β~2~AR in phospholipid vesicles ([Figure 2A](#f2){ref-type="fig"}). Factor Xa is a protease that selectively cleaves the β~2~AR within the third ICL (ICL3). Receptors oriented inside-out (ICL3 outside of lipid vesicle) will be susceptible to Factor Xa, whereas those oriented outside-out will not ([Figure 2A](#f2){ref-type="fig"}). Approximately 90% of reconstituted β~2~AR was resistant to Factor Xa, whereas all of the receptor was cleaved in the presence of 0.1% DM ([Figure 2B](#f2){ref-type="fig"}), a concentration of detergent, which permeabilizes the vesicles. These results are consistent with a predominantly outside-out orientation. PNGase F is an enzyme that cleaves asparagine-linked oligosaccharides on the extracellular N-terminus ([Figure 2A](#f2){ref-type="fig"}). Treatment of reconstituted receptor with PNGase F led to a mobility shift that was indistinguishable from that observed in the presence of 0.1% DM, consistent with predominantly outside-out orientation ([Figure 2C](#f2){ref-type="fig"}). The orientation was further confirmed using NHS-PEO~4~-biotin to chemically modify the N-terminus ([Figure 2A](#f2){ref-type="fig"}). This polar compound would not be expected to cross the lipid bilayer. Chemical modification of the N-terminal FLAG epitope results in loss of reactivity to the M1 antibody; treatment of vesicles following reconstitution resulted in the loss of M1 reactivity for more than 90% of reconstituted β~2~AR ([Figure 2D and E](#f2){ref-type="fig"}). Finally, we labelled A265C on the cytoplasmic side of the β~2~AR with monobromobimane (mBBr) and examined the ability of tryptophan in solution to quench bimane fluorescence. We observed no quenching of reconstituted, bimane-labelled β~2~AR with 1 mM tryptophan. However, solubilization of vesicles using 0.2% DM resulted in significant quenching ([Supplementary Figure 1](#S1){ref-type="supplementary-material"}). Taken together, these studies show that the β~2~AR is predominantly oriented with the extracellular domains on the outside of the vesicle.

Distribution of *β*~2~AR in lipid vesicles
------------------------------------------

In studying oligomerization, it is important to avoid forcing protein together by inhomogeneous reconstitution, that is, trapping the majority of the receptor molecules in a minor population of lipid vesicles. For instance, it has been shown previously that 90% of rhodopsin molecules were incorporated into only 10% of vesicles ([@b39]). We used isopycnic density centrifugation to assess the distribution of β~2~ARs in lipid vesicles as previously described for rhodopsin ([@b39]). Cy5-labelled β~2~ARs were reconstituted at a lipid-to-receptor ratio of 1000:1 in lipids containing NBD--phosphocholine (at a final of 0.4% of total lipid content). This allowed us to analyze samples subjected to a discontinuous sucrose density gradient by following Cy5 fluorescence (for the presence of β~2~AR) and NBD fluorescence (for the presence of lipid vesicles). Our results show nearly perfect correlation between Cy5 fluorescence and NBD fluorescence at every fraction analyzed, suggesting that β~2~AR molecules are uniformly distributed in these vesicles ([Figure 3A](#f3){ref-type="fig"}). Similar results were obtained with β~2~AR reconstituted at a 10 000:1 lipid-to-receptor ratio ([Supplementary Figure 2](#S1){ref-type="supplementary-material"}).

To assess the density of β~2~ARs in the lipid vesicles, we used electron microscopy to determine the average diameter of our β~2~AR-containing lipid vesicle preparations. Using a negative staining protocol, we determined that the average diameter of our vesicle preparations at a lipid-to-receptor ratio of 1000:1 was 83 nm±12 nm ([Figure 3B](#f3){ref-type="fig"}). Using the calculations detailed in the Supplementary Materials and methods section, we concluded that there are 50--60 β~2~ARs per lipid vesicle, with the majority oriented in an outside-out manner.

Functional characterization of *β*~2~AR in lipid vesicles
---------------------------------------------------------

We performed saturation binding on purified, reconstituted receptor to determine the affinity of all three single-cysteine mutants for the antagonist \[^3^H\]-dihydroalprenolol (DHA). We observed no significant difference between the three modified β~2~ARs and wild-type β~2~ARs ([Table I](#t1){ref-type="table"} and [Supplementary Figure 3](#S1){ref-type="supplementary-material"}). Competition binding studies with \[^3^H\]-DHA were used to determine the *K*~i~ values for the agonist isoproterenol (Iso) and the inverse agonist ICI 118,551 (ICI). As shown in [Table I](#t1){ref-type="table"} and [Figure 4](#f4){ref-type="fig"}, the values for the single-cysteine mutants are comparable to those obtained for wild-type β~2~AR, suggesting that introduction of the single-reactive cysteines and reconstitution of purified β~2~AR into lipid vesicles does not alter the pharmacology of the receptor.

Functionality for G protein coupling of the three single-cysteine mutants was addressed by \[^35^S\]-GTPγS binding. This assay involves reconstituting purified β~2~AR with purified Tet-G~αs~ as previously described ([@b55]; [@b22]). Agonist binding to all three β~2~AR single-cysteine mutants led to significant stimulation of G protein coupling that was similar to wild-type receptor ([Figure 4C](#f4){ref-type="fig"}). Treatment of samples with the inverse agonist ICI led to decreases in basal activity similar to that observed for wild-type receptor ([Figure 4C](#f4){ref-type="fig"}). Modification of the single cysteines with Cy5--maleimide fluorophore had no significant effect on G protein coupling ([Figure 4C](#f4){ref-type="fig"}; *P*\>0.05).

FRET analysis of fluorophore-labelled *β*~2~ARs in lipid bilayers
-----------------------------------------------------------------

We first determined FRET between receptors labelled at the same position. Δ5-A265C labelled with Cy3 was reconstituted with an equivalent amount of Δ5-A265C labelled with Cy5 in order to monitor TM6/TM6 interactions. This was repeated for Δ5-T66C and Δ5-R333C, as reporters for ICL1/ICL1 and H8/H8 interactions, respectively. [Figure 5A](#f5){ref-type="fig"} shows an example of a typical experiment performed on Δ5-T66C. FRET between Cy3- and Cy5-labelled receptors (30.3±1.2%) is only observed after receptor reconstitution into a lipid bilayer, but not when receptors remain solubilized in detergent ([Figure 5A](#f5){ref-type="fig"} and [Table II](#t2){ref-type="table"}). Similar observations were made for Cy3- and Cy5-labelled Δ5-A265C (16.7±1.3%) and for Cy3- and Cy5-labelled Δ5-R333C (26.9±0.8%; [Table II](#t2){ref-type="table"}).

To provide additional information about the relative orientation of β~2~AR protomers, we investigated FRET between different labelling sites. For example, Δ5-T66C labelled with Cy3 was reconstituted with an equivalent amount of Δ5-A265C labelled with Cy5 in order to examine ICL1/TM6 interactions. The same approach was followed for the other possible combinations, ICL1/H8 and TM6/H8 ([Table II](#t2){ref-type="table"}). The observation of different FRET efficiencies for different labelling pairs suggests a specific arrangement of receptors in the lipid bilayers rather than nonspecific aggregation. To further rule out the possibility that the FRET observed in these studies is simply due to crowding of labelled receptors at the lipid bilayer, a 10-fold higher molar concentration of lipids (a final lipid-to-receptor ratio of 10 000:1) was used in order to reduce the number of receptors per unit area of lipid bilayer. FRET efficiencies observed at a lipid-to-receptor ratio of 10 000:1 were not significantly different from those obtained at a ratio of 1000:1 ([Figure 5B--D](#f5){ref-type="fig"}; *P*\>0.05).

FRET saturation of fluorophore-labelled *β*~2~AR oligomers
----------------------------------------------------------

To further investigate the specificity of the observed oligomerization, as well as the stoichiometry of the oligomers, we performed FRET saturation experiments where the ratio of acceptor fluorophore (Cy5-labelled β~2~AR) to donor fluorophore (Cy3-labelled β~2~AR) is increased, while maintaining the overall receptor concentration and lipid-to-receptor ratio constant. If the energy transfer is due to specific receptor--receptor interactions, FRET efficiency will saturate as the Cy5/Cy3 ratio is increased. In contrast, random collisions should yield a quasi-linear relationship ([@b44]; [@b30]; [@b27]). We observe FRET saturation for all three β~2~AR labelling sites ([Figure 6A--C](#f6){ref-type="fig"}), demonstrating the specific nature of the interactions.

In addition, FRET saturation can provide insight into the number of protomers per oligomer. Our FRET saturation results were compared with a well described mathematical model ([@b56]; [@b44]; [@b30]; [@b27]; [@b26]) that has been used to predict the maximal energy transfer expected in energy transfer saturation experiments (FRET or BRET) for dimers, trimers, tetramers, etc. It follows that saturation will occur at a lower acceptor/donor ratio for higher-order oligomers than for simple dimers. We normalized our FRET saturation data for all three constructs and compared them with models for dimers, trimers, tetramers and higher-order oligomers (eight protomers), and found that our data are superimposed on the theoretical curve for tetramers ([Figure 6D](#f6){ref-type="fig"}).

The effect of ligand efficacy on *β*~2~AR oligomerization
---------------------------------------------------------

We examined the effects of three classes of GPCR drugs: a full agonist (isoproterenol), a neutral antagonist (alprenolol) and an inverse agonist (ICI) on FRET efficiency between different labelling sites. Upon treatment with saturating amounts (10 μM) of the full agonist isoproterenol, a small, but significant, increase in FRET was observed between TM6 and H8 ([Figure 7A](#f7){ref-type="fig"} and [Table II](#t2){ref-type="table"}; *P*\<0.05). At saturating concentrations (500 nM), alprenolol produced a similar result between TM6 and H8 ([Figure 7A](#f7){ref-type="fig"} and [Table II](#t2){ref-type="table"}; *P*\<0.05). It is not possible to say if these small changes are due to subtle changes in the relative arrangement of protomers, or small conformational changes in the receptor.

In contrast to the small changes observed with the agonist and neutral antagonist, much larger changes were observed following exposure to the inverse agonist ICI ([Figure 7A](#f7){ref-type="fig"} and [Table II](#t2){ref-type="table"}). Inverse agonists include many compounds that were originally classified as antagonists, ligands that occupy the orthosteric binding site, but do not alter receptor function. Instead, inverse agonists inhibit basal agonist-independent activity exhibited by many GPCRs, including the β~2~AR ([@b15]). Interestingly, at a saturating concentration (500 nM) of ICI, significant changes in FRET efficiency were observed for four of the six labelling pairs ([Figure 7A](#f7){ref-type="fig"} and [Table II](#t2){ref-type="table"}). The ICI-induced changes in FRET reach a maximum at 10 min ([Supplementary Figure 4](#S1){ref-type="supplementary-material"}).

The changes in FRET observed with ICI could reflect changes in the orientation of protomers or the number of protomers in the oligomeric complex. However, these changes could also be due to ligand-induced changes in the conformation of receptors that influence the mobility of the fluorophore or the polarity of its environment. We, therefore, examined the effect of isoproterenol and ICI on the intensity of the fluorescence and on the anisotropy of the fluorophores in labelled receptors. For both Cy3- and Cy5-labelled β~2~AR reconstituted individually, treatment with either isoproterenol or ICI did not induce significant changes in the intensity of the fluorescence (data not shown) or anisotropy of the fluorophores, suggesting that the change in FRET efficiencies observed upon ICI treatment are not a result of conformational changes in protomers ([Supplementary Figure 5](#S1){ref-type="supplementary-material"}).

The ICI-induced changes in FRET efficiency may be attributed to several additional factors: reorientation of protomers in the oligomers, a tighter packing of the protomers, an increase in the temporal stability of the oligomers (assuming there is an equilibrium between monomers and oligomers), and an increase in the stoichiometry of the oligomeric state (e.g., going from dimers or tetramers to higher-order oligomers). To distinguish between these possibilities, we performed FRET saturation in the presence and absence of ICI, alprenolol or isoproterenol. Samples were incubated with ligands for 30 min at room temperature and measurements were taken. Results show that in the presence of ICI the saturation curve is more similar to a model for higher-order oligomers, while alprenolol and isoproterenol appear to have no effect on the apparent oligomeric state of the receptor ([Figure 7B](#f7){ref-type="fig"}). Higher-order oligomerization was also observed for the inverse agonists carazolol and carvedilol ([Figure 7D](#f7){ref-type="fig"}).

Cross-linking was used to further address the state of multimeric assembly of the β~2~AR. We used *Bis*(NHS)PEO~5~, a homobifunctional cross-linker with a spacer length of 21.7 Å that covalently modifies ɛ-amines of lysine residues and α-amine groups at the N-termini, effectively trapping receptors that come within interacting distances. Although concerns have been raised about the potential for cross-linkers to trap transiently interacting proteins ([@b6]; [@b11]; [@b42]), it is evident that pre-incubation of samples with ICI leads to more extensive cross-linking and trapping of higher-order oligomers of reconstituted β~2~AR when compared with the unliganded, the agonist and the antagonist treated samples ([Figure 7C](#f7){ref-type="fig"} and [Supplementary Figure 6](#S1){ref-type="supplementary-material"}). Taken together, these results suggest that the β~2~AR forms higher-order oligomers in the presence of the inverse agonists ICI, carazolol and carvedilol.

To investigate the effect of ICI on the stability of interactions between protomers, we monitored FRET following addition of 0.2% DDM, a concentration of detergent that solubilizes the vesicles. We found that the decline in FRET following the addition of detergent was slower and less complete in samples pre-incubated with ICI compared with unliganded samples ([Supplementary Figure 7](#S1){ref-type="supplementary-material"}, *P*\<0.05), providing evidence that ICI also stabilizes interactions between protomers.

The effect of Gs on *β*~2~AR oligomerization
--------------------------------------------

To investigate the effect of G protein coupling on oligomerization, we performed FRET saturation experiments by reconstituting β~2~AR with a three-fold molar excess of purified Gs heterotrimer ([Figure 8](#f8){ref-type="fig"}). This concentration of G protein was chosen to ensure that sufficient G protein would be incorporated into vesicles while having a minimal effect on the reconstitution. The inclusion of Gs did not alter the orientation of the β~2~AR as determined by the susceptibility to PNGase F ([Figure 8A](#f8){ref-type="fig"}). We observed a statistically significant (*P*\<0.008) decrease in FRET saturation in the presence of Gs as compared with reconstitutions in the absence of Gs ([Figure 8B](#f8){ref-type="fig"}) for Cy5/Cy3 of 0.25, 0.5 and 1. To determine whether the effect of Gs on FRET saturation was due to nonspecific effects of reconstituting with another membrane-associated protein, we performed FRET saturation of β~2~AR in the presence of Gs and GTPγS, which uncouples β~2~AR and Gs. As shown in [Figure 8C](#f8){ref-type="fig"}, the presence of GTPγS increases, in a statistically significant manner (*P*\<0.04), FRET saturation to the values observed for β~2~AR alone. To estimate the fraction of β~2~AR that couples to Gs under these reconstitution conditions, we labelled C265 at the cytoplasmic end of TM6 with mBBr, an environmentally sensitive fluorescent probe. We previously showed that maximal coupling of Gs to β~2~AR reconstituted into HDL particles results in a decrease in the fluorescence intensity and an 18-nm shift in the maximal emission wavelength (λ~MAX~) of mBBr--β~2~AR (mBBr--β~2~AR; [@b62]). As shown in [Figure 8D](#f8){ref-type="fig"}, under reconstitution conditions used for FRET saturation experiments, Gs induced a decrease in intensity and a 4-nm shift in λ~MAX~ of mBBr--β~2~AR relative to the same reconstitution in the presence of GTPγS. Based on the shift of λ~MAX~ we estimate that approximately 20% of the reconstituted β~2~AR is coupled to Gs.

Discussion
==========

Receptor dimerization plays an essential role in the function of Family C GPCRs ([@b40]; [@b48]). However, the role of oligomerization for Family A (rhodopsin-like) GPCRs is less clear. It has been shown that monomeric rhodopsin and β~2~AR can activate their respective G proteins ([@b5]; [@b12]; [@b59]). Yet, there is convincing evidence from a variety of experimental approaches that the β~2~AR and many other Family A GPCRs exist as dimers or oligomers in the plasma membrane. Most compelling are studies that apply FRET and/or BRET technology to receptors tagged with fluorescent proteins and expressed in cultured cells ([@b4]; [@b44]; [@b45]; [@b25]), as well as studies using disulphide cross-linking to trap interactions in cell membranes to map the interface between protomers ([@b24], [@b23], [@b25]; [@b33]). Characterization of the structure (protomer organization) and dynamics of GPCR oligomers is challenging and will require integration of information from a variety of different approaches. In an effort to provide additional structural insight into the organization, stability and regulation of GPCR oligomers by ligands, we used FRET to study oligomerization of purified β~2~AR site specifically labelled with relatively small fluorescent probes and reconstituted into a model lipid bilayer. Our results show that monomeric β~2~ARs oligomerize spontaneously upon reconstitution into lipid bilayers in the absence of other cellular chaperones or scaffold proteins. FRET saturation studies suggest that the oligomers consist of more than two protomers, and are probably tetramers. Agonists have little effect on β~2~AR oligomerization, whereas inverse agonists appear to promote higher-order oligomerization and stabilize the oligomers against dissolution by detergent.

Spontaneous oligomerization of the *β*~2~AR in model lipid membranes
--------------------------------------------------------------------

In a cell membrane, proteins associate in a complex lipid environment involving mixtures of cholesterol and lipids having different polar groups, alkyl chain lengths and alkyl chain saturation. Moreover, the lipid composition of outer and inner membrane layers is different, and there may be distinct lipid domains that regulate the function of associated membrane proteins ([@b1]). β~2~AR oligomers have been observed to form during biosynthesis in the endoplasmic reticulum ([@b53]), suggesting that chaperones and other cellular proteins may also be involved in the assembly and/or maintenance of oligomers for some GPCRs. For example, oligomerization of the opioid receptor has been shown to depend on the G protein Gi ([@b36]). Nevertheless, our results show the strong tendency for purified β~2~AR to oligomerize spontaneously in a model lipid bilayer, and suggest that β~2~AR oligomerization is an intrinsic property of the receptor and does not require other cellular proteins or a specific lipid environment. However, we cannot exclude the possibility that oligomerization *in vivo* is regulated in some way by cellular proteins or specific lipid environments. It should be noted that rhodopsin, neurotensin receptor 1 and muscarinic receptors have also been observed to oligomerize following reconstitution into synthetic lipid bilayers ([@b39]; [@b38]; [@b26]), suggesting that spontaneous oligomerization might be an intrinsic property of Family A GPCRs.

Following purification from insect cell membranes, β~2~ARs exist as pure monomers in detergent solution ([@b59]). Our reconstitution experiments use a simple model lipid bilayer composed of DOPC and CHS (DOPC/CHS). In this environment we observe normal ligand binding properties and efficient G protein activation. The high degree of homogenous orientation of receptors in this lipid bilayer model suggests that there must be a non-random mechanism that controls receptor insertion. While the mechanism for this is unknown, preferential orientation has also been observed with reconstitution of rhodopsin, although in this case receptor was oriented preferentially with the N-terminus in the inside of the vesicle ([@b46]). Isopycnic density centrifugation experiments and EM images ([Figure 3](#f3){ref-type="fig"}) show that reconstitution using size-exclusion chromatography yields a homogenous distribution of receptors into lipid vesicles of an average diameter of 83 nm and an average surface area of approximately 21 600 nm^2^. Under our reconstitution conditions, we estimate that there are 50--60 β~2~AR molecules per vesicle. Based on the crystal structure of the β~2~AR, we can calculate that the surface area occupied by a single receptor is approximately 16 nm^2^. Therefore, receptors occupy less than 10% of the surface area of the vesicle, suggesting that the FRET we observe is not the result of nonspecific interactions due to high receptor density. To further exclude the possibility of nonspecific oligomerization, we reconstituted receptors at a 10-fold higher lipid-to-protein ratio and found no significant decrease in FRET efficiency ([Figure 5B--D](#f5){ref-type="fig"}, *P*\>0.05).

Organization and stability of *β*~2~AR oligomers
------------------------------------------------

Our reconstitution system, as well as current cell-based methods, is limited in the ability to precisely define the structure and stoichiometry of oligomers. Nevertheless, recent evidence from resonance energy transfer studies, cysteine cross-linking and fluorescence recovery after photobleaching (FRAP) studies suggest that the D2 dopamine receptor and the β~2~AR form higher-order oligomers (tetramers or greater) ([@b25]; [@b10]). Data from FRET studies can provide insight into the orientation of protomers within these oligomers. However, the following facts should be taken into account. First, while Cy3 and Cy5 are small relative to fluorescent and luminescent proteins, they are still large compared with amino acids and have relatively long flexible linkers tethering them to cysteine ([Figure 9A](#f9){ref-type="fig"}). As such, their precise orientation in the protein is not known and has been estimated by computational techniques. Second, both the distance between fluorophores and the orientation of fluorophores influence FRET. The orientation factor becomes a concern for highly constrained fluorophores; however, this probably is not the case here, since the anisotropy values that we observe experimentally for Cy3 and Cy5 are similar to those reported for free fluorophores in solution ([@b34]), and these values are not influenced by ligands. Third, as discussed below, the oligomers may be dynamic. While the predominant form may be a tetramer, these may exist in equilibrium with monomers, dimers and higher-order oligomers. Finally, in a tetramer several combinations of donor/acceptor pairs (0 donors, 4 acceptors; 1 donor, 3 acceptors; etc...) are possible. In such a system, the measured FRET signal will be the combination of all the individual energy transfers between every possible donor/acceptor pair, which complicates the analysis of the measured FRET signal, and thus, the estimation of protomer orientation in the tetramer.

Notably, saturation experiments ([Figure 6](#f6){ref-type="fig"}) result in a much simpler system, composed mostly of tetramers with one donor and three acceptors. This system dramatically reduces the number of energy transfer combinations and simplifies the analysis of FRET efficiencies. These values are used to propose possible monomer orientations within the tetramer. In FRET saturations studies, the greatest energy transfer is observed for H8/H8 and smallest for TM6/TM6 ([Figure 6B and C](#f6){ref-type="fig"}). These results are compatible with arrangements of oligomers involving a TM1 interface ([Figure 9C](#f9){ref-type="fig"}) previously described for the D2 dopamine receptor and rhodopsin ([@b37]; [@b25]). In contrast, an arrangement that would place TM6/TM6 fluorophores in close proximity ([Figure 9B](#f9){ref-type="fig"}) is not compatible with the lowest FRET efficiency observed for this pair ([Figure 6B](#f6){ref-type="fig"}).

While our FRET saturation experiments best fit a mathematical model for tetramers ([Figure 6D](#f6){ref-type="fig"}), our results are compatible with a dynamic equilibrium where a fraction of β~2~AR exists as monomers in equilibrium with higher-order oligomers, with the average size of the oligomer being a tetramer. This is in agreement with the observed maximal FRET saturation values of 30--45% ([Figure 6](#f6){ref-type="fig"}), lower than would be expected for stable tetramers given that R~0~ values for Cy3 and Cy5 range from 37--56 Å, depending on the biochemical system under investigation ([@b39]; [@b41]). Further evidence supporting this dynamic behaviour is the observation that the affinity of interactions between protomers is relatively weak outside of the bilayer environment, as show by the rapid dissociation of protomers upon the addition of a non-ionic detergent ([Supplementary Figure 7](#S1){ref-type="supplementary-material"}). Recent FRAP studies provide evidence that D2 dopamine receptors may also exist in a dynamic equilibrium of monomers and oligomers ([@b13]). In these studies, oligomers were only detected by FRAP after receptors formed stable covalent dimers through oxidative cross-linking of cysteines in TM4.

While a β~2~AR monomer can activate Gs ([@b59]), it is not known whether higher-order oligomers facilitate or impair coupling. Oligomers of rhodopsin ([@b5]) and NT1 receptor ([@b58]) couple less efficiently to G proteins than monomers. If higher-order oligomers impair coupling, the dynamic character of β~2~AR oligomers would ensure that a fraction of the β~2~AR would exist as monomers or dimers competent for G protein activation. Under our experimental conditions, the co-reconstitution of Gs with β~2~AR was associated with a small decrease in FRET saturation that was reversed by GTPγS ([Figure 8](#f8){ref-type="fig"}). This is compatible with G protein coupling shifting the equilibrium to lower-order oligomers.

Ligand regulation of *β*~2~AR oligomers
---------------------------------------

The effect of agonists on oligomerization has been described for several GPCRs. The results appear to be receptor specific: for some receptors no effect is observed, whereas for others, agonists induce dissociation or association ([@b4]; [@b8]; [@b35]; [@b63]; [@b51]; [@b10]). For the β~2~AR, Michelle Bouvier\'s laboratory reported a small agonist-induced increase in steady-state BRET; however, they concluded that this could be due to a small change in the steady-state oligomers or due to conformational changes in individual protomers ([@b3]). In subsequent BRET saturation studies from this laboratory ([@b44]) and fluorescence recovery after photobleaching studies from the Bünemann laboratory ([@b10]), no significant agonist-induced effect was observed. Our results with the full agonist (isoproterenol) are in agreement with these cell-based studies. Isoproterenol causes a relatively minor change in intermolecular FRET, with the only significant change occurring in the TM6/H8 FRET pair ([Figure 7A](#f7){ref-type="fig"} and [Table II](#t2){ref-type="table"}), but no change in FRET saturation ([Figure 7B](#f7){ref-type="fig"}). The results are in agreement with the model depicted in [Figure 9C and D](#f9){ref-type="fig"} where agonists induce a change in protomer conformation, but not oligomerization. We have previously shown significant agonist-induced movement of TM6 ([@b17]; [@b18], [@b19]; [@b61]) consistent with relatively large conformational changes observed in rhodopsin by DEER spectroscopy ([@b2]), and from the crystal structure of opsin ([@b47]; [@b54]). Assuming a tetramer, the movement of the cytoplasmic end of TM6 away from TM3 ([@b47]) ([Figure 9A](#f9){ref-type="fig"}) locates the fluorophore attached to TM6 towards the periphery in two of the four protomers, and towards H8 in the other two ([Figure 9D](#f9){ref-type="fig"}). Thus, the symmetric movement of TM6 in the tetramer, inwards and outwards, explains the minor changes in intermolecular FRET of TM6/TM6 observed upon agonist binding. In addition, the inward movement of TM6 towards H8 is compatible with the changes occurring in the TM6/H8 FRET pairs. Therefore, protomer packing does not appear to interfere with conformational changes involving TM6. In agreement with this, agonist-induced movement of the cytoplasmic end of TM6, as detected by an environmentally sensitive fluorophore covalently bound to C265, is similar for β~2~AR monomers (reconstituted into HDL particles) and oligomers (reconstituted into phospholipids vesicles) ([Supplementary Figure 8](#S1){ref-type="supplementary-material"}).

We were surprised to see that the most dramatic changes in intermolecular FRET were observed on exposure to the inverse agonist ICI. Most notable are increases in FRET for TM6/TM6 and ICL1/H8 ([Table II](#t2){ref-type="table"} and [Figure 7A](#f7){ref-type="fig"}). Fluorescence studies on monomeric β~2~AR may provide us with the link between the effect of an inverse agonist on the structure of the monomer and the process of oligomerization. We have previously shown that ICI does not induce major rearrangements in the structure of the monomer, but may reduce normal conformational fluctuations responsible for basal activity ([@b61], [@b62]). We speculate that this inherent flexibility may interfere with higher-order packing of the oligomers. Thus, the more constrained structure of the inverse agonist-bound receptor may be more compatible with closer packing of protomers within a tetramer ([Figure 9E](#f9){ref-type="fig"}), a higher-order packing ([Figure 9F](#f9){ref-type="fig"}) or more stable β~2~AR oligomers with fewer monomers. It has been observed that oligomers of rhodopsin ([@b5]) and NT1 receptor ([@b58]) couple less efficiently to G proteins than monomers; therefore, higher-order packing induced by the inverse agonist may restrict access of receptor to G protein. However, this higher-order packing is not required for the inverse agonist effect, as an inverse agonist can efficiently prevent coupling of monomeric β~2~AR to Gs ([@b62]). It is likely that a combination of all three effects is responsible for the ICI-induced FRET changes. The increased stability of oligomers against dissociation by detergent in the presence of ICI ([Supplementary Figure 7](#S1){ref-type="supplementary-material"}) is in agreement with closer packing of protomers, while FRET saturation ([Figure 7B](#f7){ref-type="fig"} and [Supplementary Figure 5](#S1){ref-type="supplementary-material"}) and cross-linking experiments ([Figure 7C](#f7){ref-type="fig"} and [Supplementary Figure 6](#S1){ref-type="supplementary-material"}) are in agreement with higher-order oligomers. Our results are consistent with a rearrangement of the oligomerization interfaces that has been observed for the dopamine D2 receptor upon inverse agonist binding ([@b23]), and the observation of higher-order packing of the inactive state of rhodopsin in rod outer segment membranes ([@b37]). The functional consequence of this higher-order oligomerization is not known, but could impair coupling of the β~2~AR to Gs, or be involved in the coupling of the β~2~AR to other signalling pathways. Interestingly, both ICI and carvedilol have been shown to activate MAPK through a G protein-independent, arrestin-dependent signalling pathway ([@b15]; [@b60]). The dramatic effects of ICI on oligomerization might be expected to influence ICI binding affinity or cooperativity; however, no differences in ICI binding properties were observed between β~2~AR monomers (reconstituted into HDL particles) and oligomers (reconstituted into phospholipids vesicles) (data not shown).

In conclusion, we find that the β~2~AR is capable of forming specifically oriented multimeric assemblies in a model lipid bilayer in the absence of other cellular proteins, complementing previous studies of Family A GPCRs. Although we cannot determine the oligomeric interfaces with precision, our results are compatible with models proposed for several other Family A GPCRs, where oligomerization involves primarily the TM1/H8 interface. Most unexpected was the observation that inverse agonists promoted higher-order β~2~AR oligomerization. This may alter access to other signalling proteins, providing insight into the ability of inverse agonists to inhibit basal G protein signalling or in promoting G protein-independent activation of MAPK pathways. These results suggest a potential structural link between the stabilizing effects of inverse agonists on β~2~AR monomers and the assembly of oligomers in lipid bilayers.

Materials and methods
=====================

Materials
---------

Cy3--maleimide and Cy5--maleimide were both obtained from Amersham Biosciences. \[^3^H\]-DHA and \[^35^S\]-GTPγS were purchased from Amersham and Perkin Elmer, respectively. All drugs tested were purchased from Sigma. The *Bis*(NHS)PEO~5~ homobifunctional cross-linker and NHS-PEO~4~-Biotin were purchased from Pierce.

Engineering of single-cysteine *β*~2~AR mutants
-----------------------------------------------

Site-directed mutagenesis of the β~2~AR was performed by using the human β~2~AR cDNA containing a FLAG epitope at the N-terminus as well as a six histidine tag at the C-terminus. The five reactive cysteines (out of 13 native cysteines) in the β~2~AR were mutated as follows: C77V, C265A, C327S, C378A and C406A to generate a Δ5 background ([@b17]). Mutations for the three single-reactive cysteine constructs (T66C, A265C and R333C all in Δ5) in these studies were carried out by PCR mutagenesis with *Pfu* polymerase (Stratagene, La Jolla, CA). The mutated cDNA was then digested with appropriate enzymes and cloned into the pFastBac1 (Invitrogen) vector. All constructs were confirmed by restriction enzyme analysis and DNA sequencing.

Expression and purification of *β*~2~AR from Sf9 insect cells
-------------------------------------------------------------

Sf9 insect cells were grown at 27°C in suspension cultures in ESF-921 medium (Expression Systems, CA) supplemented with 0.5 mg/ml gentamicin. The Bac-to-Bac Baculovirus Expression System (Invitrogen) was used for generating baculovirus for each of the β~2~AR constructs. β~2~AR expression was accomplished by infecting Sf9 cells at a density of ∼3 × 10^6^ cells/ml for ∼48 h. Cells now expressing receptor, as assessed by immunofluorescence, were harvested by centrifugation (15 min at 5000 *g*). Cell pellets were stored at −80°C prior to purification. β~2~AR from Sf9 cells was purified using a three-step purification procedure involving M1 anti-FLAG column, followed by alprenolol--Sepharose affinity column and a second M1 anti-FLAG column as described previously ([@b55]; [@b22]). Saturation binding of the antagonist \[^3^H\]-DHA was used to determine the concentration of functional purified β~2~AR. Detailed protocols are found in [Supplementary data](#S1){ref-type="supplementary-material"}.

Lipid preparation
-----------------

DOPC 18:1 phospholipid (Avanti Polar Lipids Inc.) and CHS (Steraloids, Inc.) were mixed and dissolved in chloroform to form a stock solution of lipids at a concentration of 20 and 10 mg/ml, respectively. DOPC and cholesterol were added to a glass vial, with DOPC at a 10-fold molar excess, and chloroform was evaporated under a fine stream of argon. The lipids were then further dried under vacuum for 1 h. The lipids were resuspended in Buffer G (20 mM HEPES, 100 mM NaCl, 1% octylglucoside, pH 7.5), vortexed and sonicated for 1 h in an ice water bath. The lipid mixture was stored at −80°C.

Fluorescence labelling and reconstitution of purified receptors
---------------------------------------------------------------

Purified β~2~ARs were labelled with two equivalents of either Cy3--maleimide or Cy5--maleimide (Amersham Biosciences) for 15 min at 4°C. Labelling reactions were quenched by adding a final of 1 mM L-cysteine.

β~2~AR was reconstituted as described previously ([@b55]). Briefly, for each mutant generated, 300-μl samples were prepared containing the following receptors for reconstitution: either Cy3--β~2~AR alone, Cy5--β~2~AR alone or both Cy3--β~2~AR and Cy5--β~2~AR. The amount of both labelled receptors and lipids used for reconstitution varied depending on the lipid-to-receptor ratio. Either 1000:1 (mol lipid:mol receptor) or 10 000:1 (mol lipid:mol receptor) conditions were used. The lipid/receptor mixture, plus reconstitution buffer to 300 μl, was mixed and placed on ice for 2 h. Vesicles were allowed to form by removing detergent on a Sephadex G-50 (fine) column (25 × 0.8 cm) using reconstitution buffer (20 mM HEPES, 100 mM NaCl, pH 7.5).

To assess the proportion of receptors incorporating into vesicles, we performed discontinuous sucrose gradients as described previously for rhodopsin ([@b39]) (see [Supplementary data](#S1){ref-type="supplementary-material"}).

The number of fluorophore molecules per reconstituted receptor was calculated by using the maximum absorbance of the donor- or acceptor-labelled receptor. The number of donor or acceptor fluorophores per β~2~AR ranged between different preps from 0.4 to 0.8 for all three constructs ([Supplementary Table 1](#S1){ref-type="supplementary-material"}).

Fluorescence spectroscopy
-------------------------

Experiments were performed at 25°C with a SPEX FluoroMax-3 spectrofluorometer (excitation and emission bandpass of 2 nm, S/R acquisition mode). The final concentration of β~2~AR used for spectroscopy was typically ∼20 nM.

For FRET experiments, spectra were taken from receptors labelled with donor (Cy3) and reconstituted together with receptors labelled with acceptor (Cy5) at the various cysteine mutants generated. Spectra of receptors labelled with only the acceptor fluorophore and reconstituted alone were also taken. For each type of receptor, two types of emission scans were acquired. The first emission scan (donor scan) acquired used the excitation maximum for the donor fluorophore Cy3 (λ~ex~=550 nm). The second emission scan (acceptor scan) used the excitation maximum for the acceptor fluorophore Cy5 (λ~ex~=649 nm). For testing the effects of β~2~AR ligands, samples±drug were mixed and incubated 20 min at RT. Three separate samples were used for testing each type of drug and individual spectra were acquired and averaged. Removal of acceptor bleed-through and correction of any drug-induced acceptor fluorescence intensity changes were carried out and described in detail previously ([@b22]) and are present in [Supplementary data](#S1){ref-type="supplementary-material"}.
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![β~2~AR single-cysteine constructs and FRET donor--acceptor pair. (**A**) Three single-reactive cysteines constructs were generated on a minimal cysteine background (Δ5-β~2~AR). The labelling sites were placed in the first ICL, Δ5-β~2~AR-T66C, at the cytoplasmic end of the sixth transmembrane segment, Δ5-β~2~AR-A265C, and helix eight, Δ5-β~2~AR-R333C. (**B**) Intracellular 3D view of the distribution of regions chosen for single-cysteine mutants, α-carbons are depicted. (**C**) FRET donor (λ~ex~=549 nm; λ~em~=570 nm) and acceptor pair (λ~ex~=650 nm; λ~em~=670 nm).](emboj2009267f1){#f1}

![β~2~ARs are predominantly oriented outside-out in lipid bilayers. (**A**) Strategies for determining orientation of β~2~AR in lipid bilayers. (**B**) Purified receptors were reconstituted as described under Materials and methods and then subjected to treatment with Factor Xa and resolved by 10% SDS--PAGE and transferred onto nitrocellulose. The presence of β~2~AR was determined by probing with an M1 antibody conjugated with Alexa-680. (**C**) Samples subjected to PNGase F were prepared and imaged as in panel A. (**D**, **E**) Reconstituted samples were treated with the hydrophilic, amine-reactive, alkylating reagent NHS-PEO~4~-biotin that disrupts binding of the M1 monoclonal antibody to the FLAG epitope. Samples were assessed for reactivity to M1 antibody (D) and an antibody that recognizes the C-terminal six-histidine tag (E). All data are representative of three independent experiments.](emboj2009267f2){#f2}

![β~2~ARs are homogenously distributed in lipid vesicles. (**A**) To determine the distribution of β~2~ARs in lipid vesicles, sucrose density gradients of samples containing 0.4% NBD--phosphocholine and Cy5--β~2~ARs reconstituted at a lipid-to-receptor ratio of 1000:1 were performed as described in the [Supplementary data](#S1){ref-type="supplementary-material"}. Detection of lipid fractions was performed by following NBD fluorescence (λ~ex~=460 nm) and receptor fractions by following Cy5 fluorescence (λ~ex~=649 nm). (**B**) Reconstituted β~2~ARs were imaged using a negative staining protocol as described in the [Supplementary data](#S1){ref-type="supplementary-material"} to determine the size distribution of vesicles and the number of receptors per vesicle. Scale bar length represents 200 nm. Data are representative of three independent experiments.](emboj2009267f3){#f3}

![Single-reactive cysteine mutants are fully functional. The affinity of the agonist isoproterenol (**A**) and the inverse agonist ICI 118,551 (**B**) was measured for all three single-cysteine mutants (Δ5-T66C, Δ5-A265C and Δ5-R333C) and wild-type receptor by competitive binding of \[^3^H\]-DHA. Results are expressed as percent of radio-ligand bound in the absence of competitor. (**C**) Functionality of the three single-cysteine mutants, unlabelled or labelled with Cy5, and wild-type receptor was determined by GTPγS binding as described in the [Supplementary data](#S1){ref-type="supplementary-material"}. \[^35^S\]-GTPγS-specific binding induced by 10 μ[M]{.smallcaps} isoproterenol (agonist response) or by 10 μ[M]{.smallcaps} ICI 118,551 (inverse agonist response) is shown as fold over basal. All functional data represent the mean±s.e.m. of three independent experiments performed in triplicate.](emboj2009267f4){#f4}

![Intermolecular FRET between Cy3- and Cy5-labelled β~2~AR is independent of other cellular proteins and is specific. (**A**) Purified, detergent-solubilized receptor protein was labelled with Cy3 or Cy5 maleimide and unreacted fluorophore was quenched with cysteine and separated from protein by gel filtration as described under Materials and methods. Cy3- and Cy5-labelled protein samples were mixed at a 1:1 molar ratio and reconstituted into phospholipids bilayers or maintained in detergent. Subtraction of the proper controls and normalization of the raw traces is described in the [Supplementary data](#S1){ref-type="supplementary-material"}. Labelled β~2~ARs were reconstituted at a 10-fold higher lipid-to-receptor ratio (10 000:1) and FRET efficiency was measured for ICL1/ICL1 (**B**), TM6/TM6 (**C**) and H8/H8 (**D**) interactions. Data are representative of at least three independent experiments (A) or represent the mean±s.e.m. of at least three independent experiments (B--D).](emboj2009267f5){#f5}

![Specificity of β~2~AR oligomerization as assessed by FRET saturation. FRET saturation involved varying the ratio of Cy5- to Cy3-labelled β~2~ARs over a range of 1:1 to 10:1 (Cy5:Cy3), while the overall β~2~AR concentration was kept constant. Saturable FRET is observed for ICL1/ICL1 (**A**), TM6/TM6 (**B**) and H8/H8 (**C**). FRET measurements were performed and calculated as described in the [Supplementary data](#S1){ref-type="supplementary-material"}. Data represent the mean±s.e.m. of at least three independent experiments. (**D**) FRET saturation data from all three constructs (A--C above) was normalized to maximal FRET efficiency and then averaged and plotted together with theoretical curves (dashed lines) for dimer, trimer, tetramer and higher-order oligomer that were generated using equation (1) in the [Supplementary data](#S1){ref-type="supplementary-material"}.](emboj2009267f6){#f6}

![β~2~AR oligomers are regulated by inverse agonists. (**A**) Treatment of FRET samples with saturating amounts of the inverse agonist ICI 118,551, agonist isoproterenol and neutral antagonist alprenolol. (**B**) FRET saturation in the presence of ligands. Isoproterenol and alprenolol led to no observable difference from the unliganded FRET saturation curve, whereas ICI 118,551 yielded to a curve that is more consistent with higher-order oligomers. (**C**) Cross-linking of reconstituted Cy5-labelled β~2~AR samples in the presence or absence of isoproterenol or ICI 118,551 was carried out as described in the [Supplementary data](#S1){ref-type="supplementary-material"}. (**D**) FRET saturation in the presence of the inverse agonists carvedilol (red) and carazolol (green). All data are reported as mean±s.e.m. (A, B, D) or are representative of at least three independent experiments (C). ^\*^ (*P*\<0.05) and ^\*\*^ (*P*\<0.005).](emboj2009267f7){#f7}

![Effect of the G protein Gs on FRET saturation of Cy5- and Cy3-labelled β~2~AR. FRET saturation was performed by varying the ratio of Cy5- to Cy3-labelled β~2~AR-R333C over a range of 1:4 to 4:1 (Cy5:Cy3), while the overall β~2~AR concentration was kept constant. Purified Gs heterotrimer was added at a molar ratio of 3 Gs:1 β~2~AR before reconstitution. (**A**) The inclusion of Gs in the reconstitution did not alter the orientation of β~2~AR in vesicles as determined by the susceptibility of reconstituted β~2~AR to PNGase F (see [Figure 3C](#f3){ref-type="fig"}). FRET saturation was significantly lower in the presence of Gs compared with β~2~AR alone (**B**) or β~2~AR and Gs with 10 μ[M]{.smallcaps} GTPγS (**C**). (**D**) β~2~AR was labelled on C265 at the cytoplasmic end of TM6 with mBBr--β~2~AR and reconstituted with Gs under the same conditions that were used for FRET saturation experiments. Gs induced a decrease in intensity and a 4-nm shift in λ~MAX~ of mBBr--β~2~AR relative to the same reconstitution in the presence of GTPγS. A two-way ANOVA was used to compare FRET values for β~2~AR, β~2~AR+Gs and β~2~AR+Gs+GTPγS at the different Cy5:Cy3 ratios. *A posteriori* statistical analysis showed significant decrease in FRET between β~2~AR and β~2~AR+Gs (*P*\<0.008), and a significant increase in FRET between β~2~AR+Gs and β~2~AR+Gs+GTPγS (*P*\<0.04) for all Cy5:Cy3 ratios except 2 and 4. No statistical differences are found between β~2~AR and β~2~AR+Gs+GTPγS.](emboj2009267f8){#f8}

![Schematic representation of possible β~2~AR oligomers. (**A**) Cytoplasmic view of the 3D structure of the β~2~AR (left) and cartoon of this footprint (right), with the centre of mass of Cy3 depicted as spheres: T66C (green), A265C (blue) and R333C (red). TM6 is depicted in the inactive conformation (top) and in the proposed active conformation as observed in the structure of opsin (bottom). (**B**) Receptor oligomerization involving the surfaces of TMs 4 or/and 5 is not compatible with our FRET results and might sterically prevent movement of TM6. (**C**) Our FRET results suggest an arrangement of protomers involving the TM1 interface. (**D**) The movement of the cytoplasmic end of TM6 upon agonist binding repositions the fluorophore outwards in two of the four protomers, and towards H8 in the other two. (**E**) Treatment with the inverse agonist ICI probably reduces conformational fluctuations responsible for basal activity, increasing the packing of the oligomers. (**F**) ICI may stabilize higher-order oligomers where TM6 is packed into the core of the oligomer, contributing to increase FRET efficiency and possibly the inactive state of the receptor.](emboj2009267f9){#f9}

###### 

Agonist, antagonist and inverse agonist binding properties for the single-reactive cysteine receptors^a^

  β~2~AR                                                                                                                                                                     *K*~i~ \[s.e. interval\] (n[M]{.smallcaps})   *K*~d~±s.e.m.         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- --------------------- ----------
  Wild type                                                                                                                                                                  355 \[203--620\]                              1.17 \[0.77--1.77\]   1.3±0.16
  Δ5-T66C                                                                                                                                                                    388 \[319--473\]                              2.09 \[1.86--2.35\]   1.8±0.21
  Δ5-A265C                                                                                                                                                                   298 \[255--348\]                              1.84 \[1.45--2.33\]   2.5±0.23
  Δ5-R333C                                                                                                                                                                   214 \[168--273\]                              1.90 \[1.59--2.27\]   2.4±0.24
  ^a^Saturation and competition binding were performed as described under Materials and methods. Data represent the mean±s.e.m. of at least three independent experiments.                                                                       
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###### 

FRET efficiencies in the absence of ligand and upon binding of agonist, neutral antagonist or inverse agonist^a^

  β~2~AR region                                                                                                                                                                                                                                                                                  No ligand±s.e.m.   +Isoproterenol±s.e.m.   *P*-value   +Alprenolol±s.e.m.   *P*-value   +ICI 118,551±s.e.m.   *P*-value
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ----------------------- ----------- -------------------- ----------- --------------------- -------------
  ICL-1/ICL-1                                                                                                                                                                                                                                                                                    30.26±1.2          31.43±0.4               0.45        29.72±4.1            0.86        34.86±1.4             0.043^\*^
  TM-6/TM-6                                                                                                                                                                                                                                                                                      16.73±1.3          17.71±2.1               0.64        21.48±0.8            0.23        27.67±2.0             0.005^\*\*^
  H-8/H-8                                                                                                                                                                                                                                                                                        26.85±0.8          29.56±1.1               0.06        31.40±3.5            0.07        28.33±1.8             0.418
  ICL-1/TM-6                                                                                                                                                                                                                                                                                     24.58±2.3          22.26±0.4               0.56        27.82±6.1            0.54        30.00±4.6             0.269
  ICL-1/H-8                                                                                                                                                                                                                                                                                      24.08±1.6          23.71±0.7               0.91        26.87±4.8            0.49        35.33±2.4             0.006^\*\*^
  TM-6/H-8                                                                                                                                                                                                                                                                                       30.98±0.7          35.27±1.5               0.01^\*^    33.63±0.2            0.05^\*^    25.33±2.0             0.005^\*\*^
  ^a^FRET efficiencies were calculated as described under Materials and methods. Data represent the mean±s.e.m. of at least three independent experiments. P-values refer to statistical comparisons between no ligand and three different ligands: isoproterenol, alprenolol and ICI 118,551.                                                                                                                 
  ^\*^*P*\<0.05; ^\*\*^*P*\<0.005.                                                                                                                                                                                                                                                                                                                                                                             
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